Elsevier

Blood Reviews

Volume 33, January 2019, Pages 63-73
Blood Reviews

Review
Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care

https://doi.org/10.1016/j.blre.2018.07.003Get rights and content

Abstract

Recent advancements in cancer care, coupled with early detection and an aging population have resulted in significant growth of cancer survivors. Long term follow up of such survivors is essential given the heightened risk for development of late effects such as secondary neoplasms, cardiovascular disease or psychosocial dysfunction among others. As more patients with hematologic malignancies are cured or managed over protracted periods of time, awareness of such issues is paramount for the practicing clinicians for optimal patient management. In this review, we describe the genesis of the field of cancer survivorship, and then it's gentle metamorphosis into multiple sub-fields currently by presenting literature relevant to late effects commonly seen in Hodgkin lymphoma, non-Hodgkin lymphoma, chronic leukemia and multiple myeloma. We will discuss the strengths and pitfalls of the existing models of survivorship care in hematologic malignancies and conclude with expert perspective on how to move the field forward.

Introduction

The number of long term cancer survivors in the United States (US) has currently exceeded 15 million with projections to surge to >20 million by the year 2026 [[1], [2], [3]]. Such increase in cancer survivors is attributable to an increased incidence of malignancy for the aging population, improved screening practices leading to earlier detection, and perhaps due to significant improvements in healthcare delivery. In our quest to cure an ever increasing number of cancer patients, it has become evident that these survivors can suffer from an array of potential late effects occurring due to acute or delayed toxicities from therapies delivered. Such late effects have physical or psychosocial consequences and can in some cases be severe, debilitating, or even life threatening.

The National Coalition for Cancer Survivorship (NCCS), in 1986, pioneered the definition of survivor as being any person diagnosed with cancer, from the time of initial diagnosis until his/her death. The National Cancer Institute (NCI) definition of a cancer survivor is somewhat similar - “an individual is considered a cancer survivor from the time of diagnosis, through the balance of his or her life. Family members, friends and caregivers are also affected by the survivorship experience and are therefore included in this definition”.

A recent review found that around 50% of patients reported one or more late effects, most commonly manifesting as fatigue, depression or pain [4]. Though the field of cancer survivorship was born in the solid cancer territory, dramatic advances in hematologic malignancies have led to increased survival, but often at a cost of increasing late complications. This has led to a progressive growth in both clinical and research aspects of survivorship in hematology. There is abundant data on survivorship aspects of hematopoietic cell transplantation (HCT), however a literature gap is identified in delineating the key survivorship aspects for hematologic malignancies in general [[5], [6], [7], [8]].

Herein, we present the literature relevant to late effects commonly seen in Hodgkin lymphoma, non-Hodgkin lymphoma, chronic leukemia and multiple myeloma. We will discuss the strengths and pitfalls of the existing models of survivorship care and conclude with expert prospective on how the field will progress.

Section snippets

Survivorship in Hodgkin lymphoma

There are approximately 9000 new cases of Hodgkin lymphoma (HL) diagnosed annually in the US amounting to 10% of all lymphomas [9]. Historically, HL was a uniformly fatal disease prior to the advent of modern combination chemotherapy and radiotherapy. Such therapy has evolved since the 1960's where it encompassed staging laparotomy with splenectomy, followed by limited or extensive field radiation. This approach evolved over time and contemporary combination chemotherapy and modern radiotherapy

Survivorship in non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) encompasses a heterogeneous collection of pathologies with different clinical courses, treatments and outcomes [43]. Depending on the subtype of NHL and stage of disease, the therapeutic recommendation can vary from watch and weight strategy to use of aggressive combination chemotherapy and radiotherapy. Furthermore, the protracted disease course of indolent lymphoma, and the need of multiple sequential therapies renders the risk assessment of such therapies less

Survivorship in chronic leukemia

Survival has significantly improved for chronic leukemia patients, particularly chronic myeloid leukemia (CML) where it currently stands at over 80% at 10 years following the introduction of tyrosine kinase inhibitors (TKI). As the number of leukemia survivors expands over time, understanding the issues faced by survivors is of utmost importance to design and establish long term follow up programs. These programs should adopt a flexible model to facilitate patient monitoring depending on the

Survivorship in myeloma

Globally, 154,000 cases of multiple myeloma are diagnosed annually with an upward trend in incidence [79]. Myeloma is considered to be a disease of limited life expectancy. However, dramatic advances in management particularly with novel agents, have led to an extended life expectancy beyond the first five years of diagnosis [80]. A recent epidemiologic study utilizing the SEER registry data indicated that besides an increase in life expectancy, the incidence rate of myeloma in the US has

Long term follow up & survivorship care plan

Continued advancements in cancer screening and therapeutic strategies led to a significant increase in long term cancer survivors. It is clear that these gains come with substantial costs to survivors and society as physical, financial, legal and other challenges surface to light. Patient's often feel unprepared for the potential of late toxicities and many would like to be more informed [96]. Furthermore, evidence suggests that such survivors may not receive recommended care for variety of

Future directions and concluding remarks

A number of societies have published guidelines on long term follow up and survivorship issues including the NCCN, ASCO, Children Oncology Group (COG) among others. It covers issues related to follow up for cancer recurrence, screening for late effects and some specific follow up recommendations per disease site. Similar guidelines also exist for screening and preventive practice following HCT which has been endorsed by numerous transplant societies across the globe [105]. To the authors'

Practice points

  • Prevalence of late effects is high among survivors of hematologic malignancies

  • The spectrum of late effects includes organ dysfunction, secondary neoplasms and psychosocial effects including financial toxicity

  • The Survivorship Care Plan is a vital document that includes a comprehensive treatment summary, expected late effects as well as surveillance recommendations

  • The Survivorship Care Plan is meant to improve awareness of patients and providers, improve surveillance and ultimately improve

Research agenda

  • Refine incidence and impact of late effects as new therapies emerge and patient survival improves

  • Examine the different models of Survivorship Care Plan delivery

  • Assess how can Survivorship Care Plan delivery mitigate the magnitude of late effects burden

Conflict of interest

None of the authors declare any relevant conflicts of interest.

References (110)

  • M. Sieniawski et al.

    Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)

    Blood

    (2008)
  • N. Heutte et al.

    Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial

    Lancet Oncol

    (2009)
  • C.H. Moskowitz et al.

    Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

    Lancet

    (2015)
  • R. Chen et al.

    Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

    Blood

    (2016)
  • S.H. Swerdlow et al.

    The 2016 revision of the World Health Organization classification of lymphoid neoplasms

    Blood

    (2016)
  • G. Sanna et al.

    Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors

    Ann Oncol

    (2007)
  • E.C. Moser et al.

    Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma

    Blood

    (2006)
  • J. Meissner et al.

    Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma

    Ann Oncol

    (2015)
  • N.L. Bartlett et al.

    Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

    Blood

    (2018)
  • P. Martin et al.

    A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)

    Ann Oncol

    (2017)
  • B.C. Medeiros et al.

    Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing

    Blood Rev

    (2018)
  • H.M. Kantarjian et al.

    Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Blood

    (2012)
  • D. Verma et al.

    Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

    Blood

    (2011)
  • M. Hoglund et al.

    Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

    Blood

    (2013)
  • M. Breccia et al.

    Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases

    Leuk Res

    (2008)
  • L.J. Costa et al.

    Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

    Blood Adv

    (2017)
  • M.A. Dimopoulos et al.

    Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Lancet Oncol

    (2016)
  • A. Palumbo et al.

    Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

    Lancet Oncol

    (2014)
  • E. Boland et al.

    Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life

    J Pain Symptom Manage

    (2013)
  • S.F. Huntington et al.

    Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study

    Lancet Haematol

    (2015)
  • S.V. Rajkumar et al.

    Next-generation multiple myeloma treatment: a pharmacoeconomic perspective

    Blood

    (2016)
  • S.M. Bluethmann et al.

    Anticipating the “silver tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States

    Cancer Epidemiol Biomarkers Prev

    (2016)
  • K.D. Miller et al.

    Cancer treatment and survivorship statistics, 2016

    CA Cancer J Clin

    (2016)
  • Cancer treatment and survivorship facts & figures

    (2012–2013)
  • M. Valdivieso et al.

    Cancer survivors in the United States: a review of the literature and a call to action

    Int J Med Sci

    (2012)
  • N.S. Majhail et al.

    Surviving the cure: long term followup of hematopoietic cell transplant recipients

    Bone Marrow Transplant

    (2013)
  • R. Siegel et al.

    Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

    CA Cancer J Clin

    (2011)
  • A.B. Mariotto et al.

    Long-term survivors of childhood cancers in the United States

    Cancer Epidemiol Biomarkers Prev

    (2009)
  • A.K. Ng et al.

    Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger

    J Clin Oncol

    (2002)
  • J.C. Arseneau et al.

    Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy

    N Engl J Med

    (1972)
  • M. Henry-Amar et al.

    Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease

    Semin Oncol

    (1990)
  • M. Schaapveld et al.

    Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma

    N Engl J Med

    (2015)
  • M.L. De Bruin et al.

    Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes

    J Clin Oncol

    (2009)
  • A.K. Ng

    Review of the cardiac long-term effects of therapy for Hodgkin lymphoma

    Br J Haematol

    (2011)
  • S. Myrehaug et al.

    Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy

    Leuk Lymphoma

    (2008)
  • L.H. Young et al.

    Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial

    JAMA

    (2009)
  • P.A. Heidenreich et al.

    Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease

    J Clin Oncol

    (2007)
  • M.L. De Bruin et al.

    Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma

    J Natl Cancer Inst

    (2009)
  • A.K. Ng et al.

    Long-term complications of lymphoma and its treatment

    J Clin Oncol

    (2011)
  • M.B. Lund et al.

    Lung function impairment in long-term survivors of Hodgkin's disease

    Ann Oncol

    (1995)
  • Cited by (0)

    View full text